Suppr超能文献

乳腺癌的免疫逃逸机制。

Mechanism of immune evasion in breast cancer.

作者信息

Wang Mozhi, Zhang Changwang, Song Yongxi, Wang Zhenning, Wang Yaojia, Luo Fang, Xu Yujie, Zhao Yi, Wu Zhonghua, Xu Yingying

机构信息

Department of Breast Surgery.

Department of Surgical Oncology and General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.

出版信息

Onco Targets Ther. 2017 Mar 14;10:1561-1573. doi: 10.2147/OTT.S126424. eCollection 2017.

Abstract

Breast cancer (BC) is the most common malignant tumor among women, with high morbidity and mortality. Its onset, development, metastasis, and prognosis vary among individuals due to the interactions between tumors and host immunity. Many diverse mechanisms have been associated with BC, with immune evasion being the most widely studied to date. Tumor cells can escape from the body's immune response, which targets abnormal components and foreign bodies, using different approaches including modification of surface antigens and modulation of the surrounding environment. In this review, we summarize the mechanisms and factors that impact the immunoediting process and analyze their functions in detail.

摘要

乳腺癌(BC)是女性中最常见的恶性肿瘤,发病率和死亡率都很高。由于肿瘤与宿主免疫之间的相互作用,其发病、发展、转移和预后存在个体差异。许多不同的机制都与乳腺癌有关,其中免疫逃逸是迄今为止研究最广泛的。肿瘤细胞可以通过不同的方式逃避机体针对异常成分和异物的免疫反应,包括修饰表面抗原和调节周围环境。在这篇综述中,我们总结了影响免疫编辑过程的机制和因素,并详细分析了它们的功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67c8/5359138/ef135798b3db/ott-10-1561Fig1.jpg

相似文献

1
Mechanism of immune evasion in breast cancer.
Onco Targets Ther. 2017 Mar 14;10:1561-1573. doi: 10.2147/OTT.S126424. eCollection 2017.
2
Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy.
Breast Care (Basel). 2016 Apr;11(2):102-7. doi: 10.1159/000446061. Epub 2016 Apr 27.
3
Role of PD-1 in Immunity and Diseases.
Curr Top Microbiol Immunol. 2017;410:75-97. doi: 10.1007/82_2017_67.
4
Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.
Front Oncol. 2018 Sep 19;8:386. doi: 10.3389/fonc.2018.00386. eCollection 2018.
5
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Cancer Lett. 2020 Jan 1;468:72-81. doi: 10.1016/j.canlet.2019.10.013. Epub 2019 Oct 9.
7
The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.
Breast Care (Basel). 2018 Mar;13(1):16-21. doi: 10.1159/000486585. Epub 2018 Feb 2.
8
The mechanisms on evasion of anti-tumor immune responses in gastric cancer.
Front Oncol. 2022 Nov 10;12:943806. doi: 10.3389/fonc.2022.943806. eCollection 2022.
9
Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.
Arch Oral Biol. 2019 Feb;98:99-107. doi: 10.1016/j.archoralbio.2018.09.017. Epub 2018 Sep 29.

引用本文的文献

3
The clinicopathological significance of BRI3BP in women with invasive breast cancer.
Transl Cancer Res. 2024 Dec 31;13(12):6837-6849. doi: 10.21037/tcr-24-1113. Epub 2024 Dec 27.
4
Coordinated inflammation and immune response transcriptional regulation in breast cancer molecular subtypes.
Front Immunol. 2024 Jun 25;15:1357726. doi: 10.3389/fimmu.2024.1357726. eCollection 2024.
5
A Nanorobotics-Based Approach of Breast Cancer in the Nanotechnology Era.
Int J Mol Sci. 2024 May 2;25(9):4981. doi: 10.3390/ijms25094981.
6
wMKL: multi-omics data integration enables novel cancer subtype identification via weight-boosted multi-kernel learning.
Br J Cancer. 2024 Apr;130(6):1001-1012. doi: 10.1038/s41416-024-02587-w. Epub 2024 Jan 26.
7
8
Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers.
Int J Mol Sci. 2023 Oct 18;24(20):15332. doi: 10.3390/ijms242015332.
10
miR155 deficiency reduces breast tumor burden in the MMTV-PyMT mouse model.
Physiol Genomics. 2022 Nov 1;54(11):433-442. doi: 10.1152/physiolgenomics.00057.2022. Epub 2022 Sep 19.

本文引用的文献

2
Immune Blockade Inhibition in Breast Cancer.
Anticancer Res. 2016 Nov;36(11):5607-5622. doi: 10.21873/anticanres.11145.
3
CCR2 Influences T Regulatory Cell Migration to Tumors and Serves as a Biomarker of Cyclophosphamide Sensitivity.
Cancer Res. 2016 Nov 15;76(22):6483-6494. doi: 10.1158/0008-5472.CAN-16-0984. Epub 2016 Sep 28.
4
Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy.
ACS Nano. 2016 Oct 25;10(10):9227-9242. doi: 10.1021/acsnano.6b01600. Epub 2016 Sep 29.
5
Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.
Oncoimmunology. 2016 Jul 11;5(8):e1207841. doi: 10.1080/2162402X.2016.1207841. eCollection 2016 Aug.
6
Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.
Ther Adv Med Oncol. 2016 Sep;8(5):360-74. doi: 10.1177/1758834016658423. Epub 2016 Jul 10.
7
Fatal attraction: TICs and MDSCs.
Cell Cycle. 2016 Oct;15(19):2545-2546. doi: 10.1080/15384101.2016.1204854. Epub 2016 Aug 30.
9
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验